Apr 20, 2021
New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated During Migraine Attack in Patients Who Were Candidates for Preventive Therapy
Lundbeck today announced new data from two abstracts for VYEPTI® (eptinezumab-jjmr), presented at the 2021 American Academy of Neurology (AAN), which is being held virtually from April 17 – 22.
Apr 13, 2021
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584).